

Zika, an emerging zoonosis, vector-borne and sexual transmission disease, a multifaceted threat to future generations

Abstract

Zika, is considered as a zoonotic, emerging vector-borne and sexual transmission disease, a threat to the next generation. The objective is to collect all the current information about Zika for providing a guideline for disease control. An intensive search of scientific literature was done in "PubMed", "Web of Knowledge", "Scopus", "Google Scholar", "SID". Result showed that this vector-borne disease is also transmitted by sexual transmission and mainly affects the forthcoming generation. Due to the novel method of transmission of the disease to humans, global collaboration about disease control is required.

Keywords: Zika, Aedes, sexual transmission, control

Introduction:

Zika disease is a zoonotic disease. The vector is *Aedes* (family: Culicidae). Transmission by female *Aedes* mosquito between sunrise and sunset, lays eggs on the surface of the stagnant water, the eggs can abide in unfavorable conditions for a long time (months). Several species of mosquitoes belonging to the subgenus *Stegomyia* and *Diceromyia* of *Aedes* are probably enzootic vectors in Asia and Africa. *Ae. albopictus* & *Ae. aegypti* are the main vectors (Fig.1). *Stegomyia*, black and white pattern, tiger mosquito, tropical and subtropical areas, feeds the blood meal during the day, prefer to live close to human habitations. The breeding places of larvae are: pottery jugs, water storage tanks, empty pots, broken bottles. *Aedes aegypti* has high vectorial capacity, feeds frequently on humans, bites multiple humans in a single meal, has an imperceptible bite, lives in nearby human habitation community, It has been the main vector of American ZIKV outbreak.

Aedes albopictus was founded in Asia at the first, a suitable vector for 22 arboviruses, despite the short flight it has spread well, spread throughout tropical and subtropical areas by commercial trades and can exist in more temperate areas than *Ae. aegypti*. Several *Aedes* spp. have been implicated, including *Ae. aegypti*, *Ae. africanus*, *Ae. hensilli*, and *Ae. albopictus* (1-4). *Aedes* mosquitoes are widely distributed globally, and native habitats of most species are warm tropical and subtropical regions (5-7). Other nonvector modes of Zika virus transmission include congenital (8), perinatal (9), and sexual (10,11). Possible transmission by blood transfusion (12,13), animal bite and laboratory exposure has been described.





Fig.1. Vectors of Zika:*Aedes aegypti*, *Ae. albopictus*

Results:

Life cycle of zika in mosquito:

Mosquitos bite the infected patient, an then take the combination of Zika virus , pass through the epithelial midgut cell, settlement in the salivary gland, incubation is 5-10 days, find in the saliva, and then can infect the human. Zika transmission routes is presented in fig. 2.




Fig.2. Zika transmission routes

The disease has sylvatic cycle which is Monkey-mosquito-monkey by *Aedes* mosquito. Urban cycle is human-mosquito-human by *Ae.aegypti* *Ae.albopictus*, *Ae.hensilii* (Fig.3).

Life cycle of virus in human:

Feeding blood by infected mosquito and then Inject the zika to skin, effect of derma and epidermal cell, pass through the lymphatic, get to blood stream and finally infect the organs and tissue

Zoophilic mosquitoes

- | | | |
|--------------------------|------------------------|---------------------------|
| <i>Ae. dalzieli</i> | <i>Ae. tarsalis</i> | <i>Ae. taeniarostris</i> |
| <i>Ae. fowleri</i> | <i>Ae. vitattus</i> | <i>Ae. tarsalis</i> |
| <i>Ae. furcifer</i> | <i>Ae. africanus</i> | <i>Ae. vitattus</i> |
| <i>Ae. luteocephalus</i> | <i>Ae. flavicollis</i> | <i>An. gambiae</i> |
| <i>Ae. metallicus</i> | <i>Ae. furcifer</i> | <i>Mansonia uniformis</i> |
| <i>Ae. minutus</i> | <i>Ae. grahami</i> | <i>Eratmapodites</i> |
| <i>Ae. neoafricanus</i> | <i>Ae. opok</i> | |

Anthropophilic mosquitoes

- Ae. aegypti*
- Ae. albopictus*
- Ae. hensilli*






Fig.3. Zika disease cycle

The Agent is Flavivirus (family:flaviviridae).Flavivirus closely related to other flaviviruses, Dengue, Yellow fever, Japanese encephalitis. It is first detected was in 1947 in the zika forest(Uganda). The zika virus was isolated on several occasions from *Ae.africanus* in 1948 . By 2000 only 12 cases of human disease had been reported, which fortunately were declared safe.

Symptoms of Zika

20% of patients show the clinical symptoms, similar to other arboviruses (as Dengue or Chikungunya), it has low grade fever, rash, arthralgia, myalgia, conjunctivitis. Its can be effect on adult, fetus and children.Clinical symptoms are: fever, rash, myalgia. Clinical symptom in18% of patients have been observed. First

endemic transmission in Brazil 240000-1300000 suspected cases. Microcephaly (Figs.4,5) .It could be infected the monkeys and others mammalian.



Fig.4. Symptoms of Zika




Fig.5. Symptoms of Zik

Global distribution of Zika

Global distribution of Zika is shown in Fig.6.





Fig.6. Global distribution of Zika

The strategy of treatment

There is no Zika virus vaccine so far. Vaccine candidates could be: nucleic acid vaccines live attenuated vaccines, inactivated whole virus vaccines and using antiviral drugs.

Personal protection

Avoidance mosquito bite, using impregnated bednets, using permethrin insecticide for clothes, using insect repellents, and using screens on windows and doors.

Discussion and conclusion:

Global strategy for disease control:

Most precarious threats for ZIKV infection are mosquitoes including their reproducing localities. Their encounter with humans must be reduced in order to control and prevent their outspread. This can be employed by using mosquito repellents, mosquito nettings and closing the entrances and openings. Insect killing sprays recommended by the WHO Pesticide Evaluation Scheme should be used as larvicides (14, 15). Insect repellents should not be used for babies under two months, mosquito nets should be used to protect babies from insect bite. Centre of disease control recommends mosquito repellents with active ingredients picaridin, DEET, eucalyptus oil, IR3535, oil of lemon and para-menthane-diol. These are safe for pregnant and lactating mothers (16). Repellants containing eucalyptus oil, lemon oil and paramenthane-diol should be avoided for children below 3 years of age. Mosquitoes should be killed using indoor mosquito killing sprays which contain active ingredient Imidacloprid and β -Cyfluthrin available in market (17). Flying insect fogger can also be used against the mosquitoes containing active

ingredients Tetramethrin and Cypermethrin. Tests against ZIKV infection should be performed before blood transfusions to prevent transfusion related transmission. Pregnancy must be avoided in the high risk ZIKV infection prone areas before complete eradication or extra care must be exercised as microcephaly is associated with ZIKV infection(18).Other strategies include the use of intracellular bacteria *Wolbachia*, which acts as a biopesticide to control mosquito population(19).Rapid suppression of new populations, expansion and amplification of monitoring of these mosquitoes, establishment of quarantine system, regular and more accurate inspection of entry from native of such disease (20-29).

Acknowledgments: This research is supported by Ministry of Health and Medical Education under code number of NIMAD 982984.

References:

1. Dick GW, Kitchen SF, Haddock AJ. Zika virus. I. Isolations and serological specificity. *Trans R Soc Trop Med Hyg.* 1952;46:509–20.
[http://dx.doi.org/10.1016/0035-9203\(52\)90042-4](http://dx.doi.org/10.1016/0035-9203(52)90042-4).
2. Marchette NJ, Garcia R, Rudnick A. Isolation of Zika virus from *Aedes aegypti* mosquitoes in Malaysia. *Am J Trop Med Hyg.* 1969;18:411–5.
3. Hayes EB. Zika virus outside Africa. *Emerg Infect Dis.* 2009;15:1347–50.
<http://dx.doi.org/10.3201/eid1509.09044>
4. Grard G, Caron M, Mombo IM, Nkoghe D, Mboui Ondo S, Jiolle D, et al. Zika virus in Gabon (Central Africa)—2007: a new threat from *Aedes albopictus*? *PLoS Negl Trop Dis.* 2014;8:e2681. <http://dx.doi.org/10.1371/journal.pntd.0002681>
5. Ledermann JP, Guillaumot L, Yug L, Saweyog SC, Tided M, Machieng P, et al. *Aedes hensillias* a potential vector of Chikungunya and Zika viruses. *PLoS Negl Trop Dis.* 2014;8:e3188. <http://dx.doi.org/10.1371/journal.pntd.0003188>

6. Kraemer MU, Sinka ME, Duda KA, Mylne A, Shearer FM, Brady OJ, et al. The global compendium of *Aedes aegypti* and *Ae. albopictus* occurrence. *Sci Data*. 2015;2:150035. <http://dx.doi.org/10.1038/sdata.2015.35>
7. Gaffigan TVWR, Pecor JE, Stoffer JA, Anderson T. Systematic catalog of culicidae. Suitland (MD): Smithsonian Institution; Silver Spring (MD): Walter Reed Army Institute of Research; 2016 [cited 2016 Feb 10]. <http://mosquitocatalog.org/>
8. Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound Obstet Gynecol*. 2016;47:6–7. <http://dx.doi.org/10.1002/uog.1583135>. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill*. 2014;19:20751. <http://dx.doi.org/10.2807/1560-7917.ES2014.19.13.20751>
10. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. *Emerg Infect Dis*. 2015;21:359–61. <http://dx.doi.org/10.3201/eid2102.141363>
11. Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. *Euro Surveill*. 2014;19:20761. <http://dx.doi.org/10.2807/1560-7917.ES2014.19.14.20761>
12. US Food and Drug Administration. Recommendations for donor screening, deferral, and product management to reduce the risk of transfusion transmission of Zika virus, recommendations for industry. 2016 Feb 16 [cited 2016

<http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM486360.pdf>

13. Simpson DI. Zika virus infection in man. *Trans R Soc Trop Med Hyg.* 1964;58:335–8. [http://dx.doi.org/10.1016/0035-9203\(64\)90201-9](http://dx.doi.org/10.1016/0035-9203(64)90201-9)

14. World Health Organization (2016) Zika virus: Fact sheet [http://www.who.int/media centre/factsheets /zika/en/](http://www.who.int/media centre/factsheets/zika/en/). Accessed 3 Feb 2016.

15. Fontes MB. Zika virus-related hypertensive iridocyclitis. *Arq Bras Oftalmol.* 2016;79:63.

16. European Centre for Disease Prevention and Control. Rapid risk assessment: ZIKV infection outbreak, Brazil and the Pacific region. 25 May 2015. [http://ecdc.europa.eu/en/publications/Publications/rapid-risk-assessment - Zika%20virus-south -america-Brazil-2015.pdf](http://ecdc.europa.eu/en/publications/Publications/rapid-risk-assessment-Zika-virus-south-america-Brazil-2015.pdf).

17. National Center for Health Statistics, key messages—ZIKV disease, Centre of disease control. <http://www.cdc.gov/zika/pdfs/zika-key-messages.pdf>.

18. Burd I, Griffin D. The chasm between public health and reproductive research: what history tells us about Zika virus. *J Assist Reprod Genet.* 2016;33:439–40

19. Benelli G, Jeffries CL, Walker T. Biological control of mosquito vectors: past, present, and future. *Insects.* 2016;7:E52

20. Díaz-Menéndez M (2017). *Zika Virus Infection Risk of Spreading in Europe.* Springer.

21. Boyer S, Calvez E, Chouin-Carneiro T, Diallo D, Failloux AB (2018) An overview of mosquito vectors of Zika virus. *MicrobInfect* 1: 20(11-12):646-60.

22. Higuera A, Ramírez JD (2019) Molecular epidemiology of dengue, yellow fever, Zika and Chikungunya arboviruses: an update. *Acta Tropica*1:190:99-111.
23. Singh RK, Dhama K, Malik YS, Ramakrishnan MA, Karthik K, Tiwari R, Saurabh S, Sachan S, Joshi SK(2016) Zika virus—emergence, evolution, pathology, diagnosis, and control: current global scenario and future perspectives—a comprehensive review. *Vet Q*36(3):150-75.
24. Hilgenfeld R, Vasudevan SG (2018) editors. *Dengue and Zika: Control and Antiviral Treatment Strategies*. Springer May 29.
25. Pattnaik A, Sahoo BR, Pattnaik AK (2020) Current Status of Zika Virus Vaccines: Successes and Challenges. *Vaccines*8(2):266.
26. Nejati J, Bueno-Marí R, Collantes F, Hanafi-Bojd AA, Vatandoost H, Charrahy Z, Tabatabaei SM, Yaghoobi-Ershadi MR, Hasanzehi A, Shirzadi MR, Moosa-Kazemi SH (2017) Potential risk areas of *Aedes albopictus* in south-eastern Iran: a vector of dengue fever, zika, and chikungunya. *Front Microbiol* 5(8):1660.
27. Song BH, Yun SI, Woolley M, Lee YM (2017) Zika virus: history, epidemiology, transmission, and clinical presentation. *J Neuroimmunol*15:308:50-64.
28. Weaver SC (2017) Emergence of epidemic Zika virus transmission and congenital Zika syndrome: Are recently evolved traits to blame?. *MBio*. 8;8(1).
29. World Health Organization (2016) Zika situation report. World Health Organization, Geneva, Switzerland. <http://www.who.int/emergencies/zika-virus/situation-report/6-october-2016/en/> .